(19)
(11) EP 1 948 782 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.09.2012 Bulletin 2012/37

(45) Mention of the grant of the patent:
01.08.2012 Bulletin 2012/31

(21) Application number: 06744545.2

(22) Date of filing: 21.04.2006
(51) International Patent Classification (IPC): 
C12N 1/20(2006.01)
 A61K 39/39(2006.01)
(86) International application number:
PCT/IB2006/000978
(87) International publication number:
WO 2006/114680 (02.11.2006 Gazette 2006/44)

(54)

VACCINE ADJUVANTS

IMPFSTOFFADJUVANTIEN

ADJUVANTS DE VACCINS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 25.04.2005 IN MU05052005

(43) Date of publication of application:
30.07.2008 Bulletin 2008/31

(73) Proprietor: Cadila Pharmaceuticals Limited
Bhat, Ahmedabad 382 210 (IN)

(72) Inventors:
  • KHAMAR, Bakulesh, Mafatlal
    Bhat Ahmedabad 382 210 Gujarat (IN)
  • MODI, Indravadan, Ambalal
    Bhat Ahmedabad 382 210 Gujarat (IN)
  • MODI, Rajiv, Indravadan
    Bhat Ahmedabad 382 210 Gujarat (IN)
  • GHOSH, Prasanta, Kumar
    Bhat Ahmedabad 382 210 Gujarat (IN)
  • DESAI, Nirav
    Bhat Ahmedabad 382 210 Gujarat (IN)

(74) Representative: Rigby, Barbara Nicole 
Dehns St Bride's House 10 Salisbury Square
London EC4Y 8JD
London EC4Y 8JD (GB)


(56) References cited: : 
WO-A2-03/049667
 WO-A2-03/075825
   
  • GORMUS BOBBY J ET AL: "Under-explored experimental topics related to integral mycobacterial vaccines for leprosy" EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 2, no. 6, 1 December 2003 (2003-12-01), pages 791-804, XP009115719 ISSN: 1476-0584
  • STILLS HAROLD F JR: "Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants" ILAR JOURNAL, vol. 46, no. 3, 1 January 2005 (2005-01-01), pages 280-293, XP001539142 ISSN: 1084-2020
  • SUR PRABIR KUMAR ET AL: "Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer)." JOURNAL OF THE INDIAN MEDICAL ASSOCIATION FEB 2003, vol. 101, no. 2, February 2003 (2003-02), page 118 , 120, XP009115704 ISSN: 0019-5847
  • SHARMA P ET AL: "Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment." LEPROSY REVIEW JUN 2000, vol. 71, no. 2, June 2000 (2000-06), pages 179-192, XP009115711 ISSN: 0305-7518
  • PETROVSKY N.: 'Vaccine Adjuvants: Current State and Future Trends' IMMUNOLOGY AND CELL BIOLOGY vol. 82, 2004, pages 488 - 496, XP009078668
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).